The Journal of infectious diseases · 2026
A Humoral Dilemma: Reassessing Monkeypox Virus Neutralizing Antibodies at More Than 2 Years From Mpox or Modified Vaccinia Ankara-Bavarian Nordic Vaccination.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moschetta Nicolò, Criscuolo Elena, Raccagni Angelo Roberto, Capra Nicolò, Lolatto Riccardo, Loi Gabriele, Canetti Diana, Castagna Antonella, Nozza Silvia, Clementi Nicola
Аннотация
BACKGROUND: The persistence of immunological memory after immunization against monkeypox virus (MPXV) is unclear. This study assessed MPXV-specific neutralizing antibodies (nAbs) at > 2 years from mpox or Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination.
METHODS: Retrospective study including individuals with previous mpox or vaccination with MVA-BN, whose MPXV-specific nAb titers were already assessed at 6 months from either event at our center. Neutralizing titers were determined at > 2 years from mpox or vaccination by plaque reduction neutralization test (positive ≥ 1:10) as the maximum dilution with reduction of cytopathic effect of 90% and 50% (IC90 and IC50). Groups were compared using χ2 test, Fisher exact test, or Wilcoxon rank-sum test. Association between titers at > 2 years and individuals characteristics was evaluated with ordinal logistic regression.
RESULTS: Overall, 48 individuals with previous mpox and 42 vaccinees were included, all were men. At > 2 years from mpox or vaccination, 22 of 90 (24.44%) and 53 of 90 (58.8%) had positive nAb titers, respectively, at IC90 and IC50. At IC50 previous mpox was associated with positive titers (68.75% vs 47.62%; P = .042), with univariate analysis associating higher titers at 6 months to higher titers at > 2 years (odds ratio [OR] = 6.45; 95% confidence interval [CI], 1.89-22.07; P = .003). In multivariate analysis, historical smallpox vaccination was associated with higher titers at > 2 years (OR = 5.37; 95% CI, 1.31-22.00; P = .020), whilst previous mpox was marginally associated (OR = 2.08; 95% CI, .94-4.62; P = .073).
CONCLUSIONS: This was a retrospective study including individuals with previous mpox or vaccination with MVA-BN whose MPXV-specific nAb titers were already assessed at 6 months from either event. MPXV-specific nAbs waned at > 2 years from previous infection or vaccination, often becoming undetectable. Higher nAb titers at 6 months (univariate) and prior smallpox vaccination (multivariate) were associated with nAb detection at > 2 years, whilst previous mpox was marginally associated.
METHODS: Retrospective study including individuals with previous mpox or vaccination with MVA-BN, whose MPXV-specific nAb titers were already assessed at 6 months from either event at our center. Neutralizing titers were determined at > 2 years from mpox or vaccination by plaque reduction neutralization test (positive ≥ 1:10) as the maximum dilution with reduction of cytopathic effect of 90% and 50% (IC90 and IC50). Groups were compared using χ2 test, Fisher exact test, or Wilcoxon rank-sum test. Association between titers at > 2 years and individuals characteristics was evaluated with ordinal logistic regression.
RESULTS: Overall, 48 individuals with previous mpox and 42 vaccinees were included, all were men. At > 2 years from mpox or vaccination, 22 of 90 (24.44%) and 53 of 90 (58.8%) had positive nAb titers, respectively, at IC90 and IC50. At IC50 previous mpox was associated with positive titers (68.75% vs 47.62%; P = .042), with univariate analysis associating higher titers at 6 months to higher titers at > 2 years (odds ratio [OR] = 6.45; 95% confidence interval [CI], 1.89-22.07; P = .003). In multivariate analysis, historical smallpox vaccination was associated with higher titers at > 2 years (OR = 5.37; 95% CI, 1.31-22.00; P = .020), whilst previous mpox was marginally associated (OR = 2.08; 95% CI, .94-4.62; P = .073).
CONCLUSIONS: This was a retrospective study including individuals with previous mpox or vaccination with MVA-BN whose MPXV-specific nAb titers were already assessed at 6 months from either event. MPXV-specific nAbs waned at > 2 years from previous infection or vaccination, often becoming undetectable. Higher nAb titers at 6 months (univariate) and prior smallpox vaccination (multivariate) were associated with nAb detection at > 2 years, whilst previous mpox was marginally associated.